CAR T treatment for acute myeloid leukemia in children and adults
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 2 years
- Your leukemia cells must show specific target markers on a lab test (immunostaining or flow cytometry)
- Be able to do daily activities reasonably well (Karnofsky score above 80) and expected to live more than 2 months
- Have acceptable heart, lung, liver, and kidney test results
- Have enough blood counts (hemoglobin at least 80 g/L)
- Be able and willing to understand the study and sign written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.